Drug Type Biosimilar |
Synonyms SYS6036 |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Biliary Tract Neoplasms | IND Approval | China | 22 Aug 2025 | |
| Colorectal Cancer | IND Approval | China | 22 Aug 2025 | |
| Esophageal Carcinoma | IND Approval | China | 22 Aug 2025 | |
| Hepatocellular Carcinoma | IND Approval | China | 22 Aug 2025 | |
| Melanoma | IND Approval | China | 22 Aug 2025 | |
| Microsatellite Instability-high Solid Tumors | IND Approval | China | 22 Aug 2025 | |
| Mismatch repair-deficient Solid Tumors | IND Approval | China | 22 Aug 2025 | |
| Non-Small Cell Lung Cancer | IND Approval | China | 22 Aug 2025 | |
| Squamous Cell Carcinoma of Head and Neck | IND Approval | China | 22 Aug 2025 | |
| Stomach Cancer | IND Approval | China | 22 Aug 2025 |






